9th February 2026
9th January 2026
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering
16th December 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
22nd September 2025
The Endpoints 11: Umoja Biopharma looks to finally break through the barriers that restrict CAR-T
16th September 2025
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
26th June 2025
Chris Bardon is featured with UBS CIO Mark Haefele on the AACR Believe in Progress podcast
25th June 2025
āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)
28th May 2025
Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types
31st March 2025
Orna Therapeutics Appoints Joseph Bolen, Ph.D., an MPM BioImpact Entrepreneur Partner, as Chief Executive Officer
28th March 2025